Key statistics
On Friday, Immunic Inc (IMUX:NSQ) closed at 1.10, 13.40% above the 52 week low of 0.97 set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.12 |
---|---|
High | 1.12 |
Low | 1.06 |
Bid | 1.08 |
Offer | 1.11 |
Previous close | 1.11 |
Average volume | 999.68k |
---|---|
Shares outstanding | 90.08m |
Free float | 86.98m |
P/E (TTM) | -- |
Market cap | 99.99m USD |
EPS (TTM) | -1.24 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- EQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
- EQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
- EQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November
- EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
- EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
- EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
- EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
More ▼